The orders relate to the company´s technology platform PreciseInhale® and DissolvIt® designed to deliver controlled and high-precision inhalation exposures for preclinical research.

“These orders confirm a continued strong interest in our technology from our existing customer base and leading pharmaceutical companies”, says Manoush Masarrat, CEO of Inhalation Sciences.

“We see increased client activity as more companies discover the benefits of our unique technology platform, particularly considering a changing regulatory landscape where more precise, efficient and cost-effective inhalation testing methods are needed. Our solutions enable significant time and cost savings while improving data quality, which is becoming increasingly important for drug development.”

For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.